1. Andressen KW, Manfra O, Brevik CH, Ulsund AH, Vanhoe nacker P, Levy FO, et al. The atypical antipsychotics clozapine and olanzapine promote down-regulation and display func tional selectivity at human 5-HT 7 receptors. British Journal of Pharmacology 2015; 172: 3846–3860. doi: 10.1111/bph.13169.
2.
Carpenter WT and Davis JM. Another view of the history of antipsychotic drug discovery and development, Molecular Psychiatry. Nature Publishing Group 2012; 17(12): 1168–1173. doi: 10.1038/mp.2012.121.
3.
Charakterystyka Produktu Leczniczego: Latuda.
4.
Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lur asidone drug-drug interaction studies: a comprehensive review. Drug. Metabol. Drug. Interact. 2014: 29(3): 191–202. https://doi.org/10.1515/dmdi-2014-0005.
5.
Citrome L. Iloperidone, Asenapine, and Lurasidone: A Brief Overview of 3 New Second-Generation Antipsychotics. Post graduate Medicine 2011; 123(2): 153–162.
6.
Citrome LA. Review of the pharmacology, efficacy and toler ability of recently approved and upcoming oral antipsychot ics: an evidence-based medicine approach. CNS Drugs 2013; 27(11): 879-911; https://doi.org/10.1007/s40263-013-0105-7.
7.
Citrome L. The ABC’s of dopamine receptor partial agonists – aripiprazole , brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract 2015; 69(11): 1211–1220.
8.
Das S, Barnwal P, Winston A B, Mondal S, Saha I. Brexpip razole: so far so good. Ther Adv Psychopharmacol 2016; 6(1):39–54. doi: 10.1177/2045125315614739.
9.
Farde, L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Positron Emission Tomography Studies on D2 and 5HT2 Receptor Binding in Risperidone-treated Schizo phrenic Patients’, Journal of Clinical Psychopharmacolo gy1995;15(1): 19–23.
10.
Findling RL, Chiu YY, Silva R, Jin F, Pikalov, et al. (2015). Pharmacokinetics and Tolerability of Lurasidone in Chil dren and Adolescents With Psychiatric Disorders’, Clinical Therapeutics. Elsevier 201537(12): 2788–2797. Doi: 10.1016/j.clinthera.2015.11.001.
11.
Frankel JS, Schwartz T L. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole’, Therapeutic Advances in Psychopharmacology 2017; 7(1): 29–41. Doi: 10.1177/2045125316672136.
12.
Gogolla N. The insular cortex. Current Biology. Elsevier 2017; 27(12), pp. R580–R586. Doi: 10.1016/j.cub.2017.05.010.
13.
Gorostowicz A, Wasik A, Siwek M. Wyzwania współczesnej farmakoterapii schizofrenii i choroby afektywnej dwubie gunowej. W: Nowe leki przeciwpsychotyczne (red. Siwek M), Medical Education, Warszawa 2020, s. 9–22.
14.
Greenberg WM, Citrome L. Pharmacokinetics and Pharma codynamics of Lurasidone Hydrochloride, a Second-Gener ation Antipsychotic: A Systematic Review of the Published Literature. Clinical Pharmacokinetics. Springer Interna tional Publishing 2016. Doi: 10.1007/s40262-016-0465-5.
15.
Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in pa tients with schizophrenia: A short-term placebo- and ac tive-controlled study followed by a 6-month double-blind. European Neuropsychopharmacology. Elsevier 2013; 23(11): 1373–1382. Doi: 10.1016/j.euroneuro.2013.08.003.
16.
Harvey PD, Siu CO, Ogasa M, Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia : Post-hocanalysis of a long-term, double-blind continuation study. Schizophrenia Research. Elsevier B.V.2015; 166(1–3): 334–338. Doi: 10.1016/j.schres.2015.06.008.
17.
Harvey PD, Siu CO and Loebel AD. Change in daytime sleepi ness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophre nia’, Schizophrenia Research: Cognition. The Authors 2016; 5: 7–12. Doi: 10.1016/j.scog.2016.05.002.
18.
Hedlund PB, Sutcliffe JG. Functional, molecular and pharma cological advances in 5-HT 7 receptor research’, TRENDS in Pharmacological Sciences 2004; 25(9): 5–10; Doi: 10.1016/j.tips.2004.07.002.
19.
Hu, C, Wang Y, Song R, Yu C, Luo X, Jia J. Single- and Mul tiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects’, Clinical Drug In vestigation. Springer International Publishing, (966) 2017. Doi: 10.1007/s40261-017-0546-8.
20.
Huang M, Kwon S, Rajagopal L, He W, Meltzer HY, et al. 5-HT 1A parital agonism and 5-HT 7 antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate , dopamine , acetylcholine and GABA’, Psy chopharmacology 2018; 235(10): 2795–2808.
21.
Jaeschke R, Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, Styczeń K, Datka W. Pharmacological Reports Lurasidone: The 2016 update on the pharmacology , efficacy and safety profile, Pharmacological Reports xxx 2016; 68(4): 748–55. Doi: 10.1016/j.pharep.2016.04.002.
22.
Latuda Prescribing Information (2012).
23.
Law V, Knox C, Djoumbou Y, Jewison T, Guo ACh, Liu Y. Drug Bank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014; 42(1): D1091–1097.
24.
Leucht, S. Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. American Journal of Psychiatry 2019; 1–12. Doi: 10.1176/appi.ajp.2019.19010034.
25.
Loebel AD, Silva R, Goldman R, Watabe K, Cucchiaro J, Cit rome L, et al. Lurasidone Dose Escalation in Early Nonre sponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study’, Journal of Clinical Psychiatry 2016; 77: 1672–1680.
26.
Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers. Neuropsychopharmacology 1996; (14): 301–307.
27.
Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, et al. A PET Study of Dopamine D 2 and Serotonin 5-HT 2 Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone’, Am J Psychiatry 2004; 161: 818–825.
28.
Meyer JM, Loebel AD and Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009; 18(11): 1715–1726.
29.
Mauri MC, et al. (2018). ‘Clinical Pharmacokinetics of Atyp ical Antipsychotics: An Update’, Clinical Pharmacokinet ics. Springer International Publishing, 2018. Doi: 10.1007/s40262-018-0664-3.
30.
Murai T, Nakako T, Ikeda K, Ikejiri M, Ishiyama T, Taiji M. Lack of dopamine D4 receptor affinity contributes to the pre cognitive effect of lurasidone’, Behavioural Brain Research. Elsevier B.V. 2015; 261: 26–30. Doi: 10.1016/j.bbr.2013.11.036.
31.
Nordstrom A, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, et al. Central D2-Dopamine Receptor Occupancy in Relation to Antipsychotic Drug Effects: A Double- Blind PET Study of Schizophrenic Patients. Biol Psychiatry 1993; 33: 227–235.
32.
Okada M, Fukuyama K, Okubo R, Shiroyama T, Yuto Ueda Y. Lurasidone Sub-Chronically Activates Serotonergic Trans mission via Desensitization of 5-HT1A and 5-HT7 Receptors in Dorsal Raphe Nucleus. Pharmaceuticals 2019; 12(149) (a).
33.
Okada M, Fukuyama K, Ueda Y. Lurasidone inhibits NMDA receptor antagonist – induced functional abnormality of thalamocortical glutamatergic transmission via 5-HT 7 receptor blockade. Br J Pharmacol 2019; 1–17. Doi: 10.1111/bph.14804 (b).
34.
Olten B, Bloch MH. Meta regression: Relationship be tween antipsychotic receptor binding profiles and side-ef fects. Progress in Neuropsychopharmacology & Biological Psychiatry 2018; Elsevier Inc, 84: 272–281. doi: 10.1016/j.pnpbp.2018.01.023.
35.
Potkin SG, Keator DB, Kesler-West ML, Nguyen DD, van Erp TG, Mukherjee J. (2014) ‘D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schi zoaffective disorder. CNS Spectrums 2014; 19:176–181. Doi: 10.1017/S109285291300059X.
36.
Preskorn S, Ereshefsky L, Chiu YY, Poola N, Loebel A. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies †’, Hum Psy chopharmacol Clin Exp 2013, 28: 495–505. Doi: 10.1002/hup.
37.
Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood dis orders and schizophrenia. Nat Rev Drug Discov 2004; 3(4): 353–9.
38.
Siwek M. Interakcje nowych leków przeciwpsychotycznych. W: Nowe leki przeciwpsychotyczne (red. Siwek M), Medical Education, Warszawa 2020, s. 245–255.
39.
Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M et al. Safety, tolerability, and risks associated with first- and second- generation antipsychotics : a state of-the-art clinical review. Therapeutics and Clinical Risk Management 2017; 13: 757–777. Sunovion Pharmaceuticals Inc. Latuda (Lurasidone hydrochloride) package insert. Marlborough (MA): Sunovion Pharmaceuticals Inc; 2013.
40.
Spina E, Hiemke C and De Leon J. Assessing drug-drug in teractions through therapeutic drug monitoring when ad ministering oral second-generation antipsychotics. Expert Opinion on Drug Metabolism and Toxicology 2016; 12 (4): 407–422.
41.
Sutton SC, Nause R, Gandelman K. The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption’. The AAPS Journal 2017. Doi: 10.1208/s12248-017-0065-9.
42.
Takekita Y, Fabbri C, Kato M, Koshikawa Y, Tajika A, Kinoshi ta T et al. HTR1A polymorphisms and clinical efficacy of anti psychotic drug treatment in schizophrenia: A meta-analysis. International Journal of Neuropsychopharmacology 2015; 19 (5).Tian Y, Zalesky A, Bousman Ch, Pantelis C, Everall I. Insula functional connectivity in schizophrenia: Subregions, gradients and symptoms. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. Society of Biological Psy chiatry 2019. doi: 10.1016/j.bpsc.2018.12.003.
43.
Tyler MW, Zaldivar-Diez J, Haggarty SJ. Classics in Chemical Neuroscience: Haloperidol. ACS Chemical Neurosciene 2017; 8: 444–453. Doi: 10.1021/acschemneuro.7b00018.
44.
Wasik, A., Krupa, A., and Siwek, M., 2019. Interactions of an tidepressants, mood-stabilisers and antipsychotics with food. Pharmacotherapy in Psychiatry and Neurology, 35 (1), 51–74.
45.
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank data base for 2018. Nucleic Acids Res 2017 Nov 8. doi: 10.1093/nar/gkx1037.
46.
Wolke SA, Mehta MA, O’Daly Zelaya OF , Zahreddine N, Keren H et al. Modulation of anterior cingulate cortex re ward and penalty signalling in medication-naive young adult subjects with depressive symptoms following acute dose lurasidone. Psychological Medicine 2019; 49: 1365–1377.
47.
Wong DF et al. Determination of dopamine D 2 receptor oc cupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology 2013; 229(2): 245–52. doi: 10.1007/s00213-013-3103-z.
48.
Woroń J, Siwek M, Wasik A. Interakcje leków w psychiatrii. Gdańsk 2019, AsteriaMed.
49.
Woroń J, Siwek M. O interakcjach i powikłaniach farma koterapii. W: Psychiatria w medycynie. T. 3: Dialogi interdy scyplinarne. Rymaszewska, J., Dudek, D. (red.). Warszawa, 2018, Medical Education, 203-227.
50.
Wylie KP and Tregellas JR. The Role of the Insula in Schizo phrenia. Schizophr Res 2010; 123(2–3): 93–104. Doi: 10.1016/j.schres.2010.08.027.
51.
Yoshikawa A, Li J and Meltzer HY. A functional HTR1A poly morphism, rs6295, predicts short-term response to lurasi done : confirmation with meta-analysis of other antipsychot ic drugs. The Pharmacogenomics Journal 2019. Springer US. Doi: 10.1038/s41397-019-0101-5.
